Murthy, Sanjay K.; Kiesslich, Ralf
Evolving endoscopic strategies for detection and treatment of neoplastic lesions in inflammatory bowel diseaseGASTROINTESTINAL ENDOSCOPY. Bd. 77. H. 3. 2013 S. 351-359
Schuppan, Detlef; Kim, Yong Ook
Evolving therapies for liver fibrosisJOURNAL OF CLINICAL INVESTIGATION. Bd. 123. H. 5. 2013 S. 1887-1901
Glessmer, S.; Maass, T.; Fehlauer, F. et al.
Extending the Evaluation Program of the Winston-Lutz-Analyzer for EPID Images of the Winston-Lutz TestSTRAHLENTHERAPIE UND ONKOLOGIE. Bd. 189. 2013 S. 142-142
Sprinzl, Martin F.; Galle, Peter R.
Facing the dawn of immunotherapy for hepatocellular carcinomaJOURNAL OF HEPATOLOGY. Bd. 59. H. 1. 2013 S. 9-10
Zeuzem, Stefan; Soriano, Vincent; Asselah, Tarik et al.
Faldaprevir and Deleobuvir for HCV Genotype 1 InfectionNEW ENGLAND JOURNAL OF MEDICINE. Bd. 369. H. 7. 2013 S. 630-639
Sulkowski, Mark S.; Bourliere, Marc; Bronowicki, Jean-Pierre et al.
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trialHEPATOLOGY. Bd. 57. H. 6. 2013 S. 2155-2163
Sulkowski, Mark S.; Asselah, Tarik; Lalezari, Jacob et al.
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype1 HCV: SILEN-C1 trialHEPATOLOGY. Bd. 57. H. 6. 2013 S. 2143-2154
Ferenci, P.; Asselah, T.; Foster, G. R. et al.
FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIALJOURNAL OF HEPATOLOGY. Bd. 58. 2013 S. S569-S570
Ferenci, P.; Asselah, T.; Foster, G. R. et al.
Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: Final results from startverso1, a randomised, double-blind, placebo-controlled phase III trialJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. Bd. 28. 2013 S. 157-158
Moreno, Christophe; Ferenci, Peter; Asselah, Tarik et al.
Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naive Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 TrialAMERICAN JOURNAL OF GASTROENTEROLOGY. Bd. 108. 2013 S. S145-S145